{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:49:42Z","timestamp":1787003382333,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Preclinical models and clinical studies have shown that anti-CD20-based treatment has multifaceted consequences on T-cell immunity. We have performed a prospective study of peripheral T-cell compartment in FL patients, all exhibiting high tumor burden and receiving rituximab-chemotherapy-based regimen (R-CHOP). Before treatment, FL patients harbor low amounts of peripheral naive T cells, but high levels of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EM<\/jats:sub>\n                    , CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>reg<\/jats:sub>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>EMRA<\/jats:sub>\n                    subsets and significant amounts of CD38\n                    <jats:sup>+<\/jats:sup>\n                    HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    activated T cells. A portion of these activated\/differentiated T cells also expressed PD-1 and\/or TIGIT immune checkpoints. Hierarchical clustering of phenotyping data revealed that 5\/8 patients with only a partial response to R-CHOP induction therapy or with disease progression segregate into a group exhibiting a highly activated\/differentiated T cell profile and a markedly low proportion of naive T cells before treatment. Rituximab-based therapy induced a shift of CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells toward a central memory phenotype and of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells to a naive phenotype. In parallel, a decrease in the number of peripheral T cells expressing both PD-1 and TIGIT was detected. These observations suggest that the standard rituximab-based therapy partially reverts the profound alterations observed in T-cell subsets in FL patients, and that blood T-cell phenotyping could provide a better understanding of the mechanisms of rituximab-based treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-50029-y","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T06:04:52Z","timestamp":1568700292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen"],"prefix":"10.1038","volume":"9","author":[{"given":"B.","family":"Milcent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Josseaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-6466","authenticated-orcid":false,"given":"F.","family":"Petitprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Riller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Toubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Teillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sib\u00e9ril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"key":"50029_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman, A. Follicular lymphoma: 2018 update on diagnosis and management. Am. J. Hematol. 93, 296\u2013305 (2018).","journal-title":"Am. J. Hematol."},{"key":"50029_CR2","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann, W. et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 106, 3725\u20133732 (2005).","journal-title":"Blood."},{"key":"50029_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 377, 42\u201351 (2011).","journal-title":"Lancet."},{"key":"50029_CR4","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"50029_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic, V. et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 128, 1112\u20131120 (2016).","journal-title":"Blood."},{"key":"50029_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet, S. et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 19, 549\u2013561 (2018).","journal-title":"Lancet Oncol."},{"key":"50029_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159\u20132169 (2004).","journal-title":"N. Engl. J. Med."},{"key":"50029_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas, A. M. et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J. Clin. Oncol. 25, 390\u2013398 (2007).","journal-title":"J. Clin. Oncol."},{"key":"50029_CR9","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","volume":"111","author":"RJ Byers","year":"2008","unstructured":"Byers, R. J. et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood. 111, 4764\u20134770 (2008).","journal-title":"Blood."},{"key":"50029_CR10","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","volume":"24","author":"T Alvaro","year":"2006","unstructured":"Alvaro, T. et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 24, 5350\u20135357 (2006).","journal-title":"J. Clin. Oncol."},{"key":"50029_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","volume":"13","author":"BE Wahlin","year":"2007","unstructured":"Wahlin, B. E., Sander, B., Christensson, B. & Kimby, E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin. Cancer Res. 13, 388\u2013397 (2007).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR12","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","volume":"27","author":"J Carreras","year":"2009","unstructured":"Carreras, J. et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 27, 1470\u20131476 (2009).","journal-title":"J. Clin. Oncol."},{"key":"50029_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/CCO.0b013e32833d5938","volume":"22","author":"JG Gribben","year":"2010","unstructured":"Gribben, J. G. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr. Opin. Oncol. 22, 424\u2013430 (2010).","journal-title":"Curr. Opin. Oncol."},{"key":"50029_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin, B. E. et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin. Cancer Res. 16, 637\u2013650 (2010).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR15","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","volume":"17","author":"BE Wahlin","year":"2011","unstructured":"Wahlin, B. E. et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin. Cancer Res. 17, 4136\u20134144 (2011).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.beha.2011.02.007","volume":"24","author":"D de Jong","year":"2011","unstructured":"de Jong, D. & Fest, T. The microenvironment in follicular lymphoma. Best Pract. Res. Clin. Haematol. 24, 135\u2013146 (2011).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"50029_CR17","first-page":"810","volume":"10","author":"ZZ Yang","year":"2012","unstructured":"Yang, Z. Z. & Ansell, S. M. The tumor microenvironment in follicular lymphoma. Clin. Adv. Hematol. Oncol. 10, 810\u2013818 (2012).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"50029_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","volume":"24","author":"P Am\u00e9-Thomas","year":"2014","unstructured":"Am\u00e9-Thomas, P. & Tarte, K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin. Cancer Biol. 24, 23\u201332 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"50029_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14201","volume":"175","author":"YN Blaker","year":"2016","unstructured":"Blaker, Y. N. et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br. J. Haematol. 175, 102\u2013114 (2016).","journal-title":"Br. J. Haematol."},{"key":"50029_CR20","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/blood-2007-08-105395","volume":"111","author":"S Mittal","year":"2008","unstructured":"Mittal, S. et al. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 111, 5359\u20135370 (2008).","journal-title":"Blood."},{"key":"50029_CR21","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","volume":"117","author":"P Christopoulos","year":"2011","unstructured":"Christopoulos, P. et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 117, 3836\u20133846 (2011).","journal-title":"Blood."},{"key":"50029_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","volume":"122","author":"ZZ Yang","year":"2012","unstructured":"Yang, Z. Z. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122, 1271\u20131282 (2012).","journal-title":"J. Clin. Invest."},{"key":"50029_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","volume":"121","author":"JH Myklebust","year":"2013","unstructured":"Myklebust, J. H. et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 121, 1367\u20131376 (2013).","journal-title":"Blood."},{"key":"50029_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.13574","volume":"94","author":"D de Jong","year":"2009","unstructured":"de Jong, D. et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 94, 70\u201377 (2009).","journal-title":"Haematologica."},{"key":"50029_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.humpath.2017.03.023","volume":"64","author":"L Xerri","year":"2017","unstructured":"Xerri, L. et al. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. Hum. Pathol. 64, 128\u2013136 (2017).","journal-title":"Hum. Pathol."},{"key":"50029_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nri2729","volume":"10","author":"FE Lund","year":"2010","unstructured":"Lund, F. E. & Randall, T. D. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat. Rev. Immunol. 10, 236\u2013247 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"50029_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12016-008-8074-1","volume":"34","author":"A Kessel","year":"2008","unstructured":"Kessel, A., Rosner, I. & Toubi, E. Rituximab: beyond simple B cell depletion. Clin. Rev. Allergy Immunol. 34, 74\u201379 (2008).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"50029_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","volume":"116","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s, R., G\u00e9liz\u00e9, E., Fridman, W. H. & Teillaud, J. L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 116, 926\u2013934 (2010).","journal-title":"Blood."},{"key":"50029_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/leu.2014.275","volume":"29","author":"C Deligne","year":"2015","unstructured":"Deligne, C., Metidji, A., Fridman, W. H. & Teillaud, J. L. Anti-CD20 therapy induces a memory Th1 response through the IFN-\u03b3\/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia. 29, 947\u2013957 (2015).","journal-title":"Leukemia."},{"key":"50029_CR30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","volume":"161","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo, D. J. & Ravetch, J. V. Differential Fc-Receptor Engagement Drives an Anti-Tumor Vaccinal Effect. Cell. 161, 1035\u20131045 (2015).","journal-title":"Cell."},{"key":"50029_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1078-0432.CCR-16-0040","volume":"23","author":"Z Ren","year":"2017","unstructured":"Ren, Z. et al. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Clin. Cancer Res. 23, 193\u2013203 (2017).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1742-4933-5-6","volume":"5","author":"S Koch","year":"2008","unstructured":"Koch, S. et al. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun. Ageing. 5, 6, https:\/\/doi.org\/10.1186\/1742-4933-5-6 (2008).","journal-title":"Immun. Ageing."},{"key":"50029_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fimmu.2017.00146","volume":"8","author":"D Saavedra","year":"2017","unstructured":"Saavedra, D., Garcia, B. & Lage, A. T cell subpopulations in healthy elderly and lung cancer patients: Insights from Cuban Studies. Front. Immunol. 8, 146, https:\/\/doi.org\/10.3389\/fimmu.2017.00146 (2017).","journal-title":"Front. Immunol."},{"key":"50029_CR34","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/leu.2014.84","volume":"28","author":"ZZ Yang","year":"2014","unstructured":"Yang, Z. Z. et al. TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma. Leukemia. 28, 1872\u20131884 (2014).","journal-title":"Leukemia."},{"key":"50029_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1158\/1078-0432.CCR-17-2337","volume":"24","author":"SE Josefsson","year":"2018","unstructured":"Josefsson, S. E. et al. T cells expressing checkpoint receptor TIGIT are enriched in Follicular Lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling. Clin. Cancer Res. 24, 870\u2013881 (2018).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.1","volume":"5","author":"ZZ Yang","year":"2015","unstructured":"Yang, Z. Z. et al. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 5, e281, https:\/\/doi.org\/10.1038\/bcj.2015.1 (2015).","journal-title":"Blood Cancer J."},{"key":"50029_CR37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3389\/fimmu.2017.00950","volume":"8","author":"C Deligne","year":"2017","unstructured":"Deligne, C., Milcent, B., Josseaume, N., Teillaud, J. L. & Sib\u00e9ril, S. Impact of depleting therapeutic monoclonal antibodies on the host adaptive immunity: a bonus or a malus? Front. Immunol. 8, 950, https:\/\/doi.org\/10.3389\/fimmu.2017.00950 (2017).","journal-title":"Front. Immunol."},{"key":"50029_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fimmu.2013.00455","volume":"4","author":"A Legat","year":"2013","unstructured":"Legat, A., Speiser, D. E., Pircher, H., Zehn, D. & Fuertes Marraco, S. A. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than \u201cExhaustion\u201d of Human CD8\u2009T Cells. Front. Immunol. 4, 455, https:\/\/doi.org\/10.3389\/fimmu.2013.00455 (2013).","journal-title":"Front. Immunol."},{"key":"50029_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","volume":"7","author":"SE Josefsson","year":"2019","unstructured":"Josefsson, S. E. et al. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol. Res. 7, 355\u2013362 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"50029_CR40","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1073\/pnas.0437875100","volume":"100","author":"SP Bohen","year":"2003","unstructured":"Bohen, S. P. et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl. Acad. Sci. USA 100, 1926\u20131930 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50029_CR41","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.celrep.2019.01.085","volume":"26","author":"ZZ Yang","year":"2019","unstructured":"Yang, Z. Z. et al. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep. 26, 2178\u20132193 (2019).","journal-title":"Cell Rep."},{"key":"50029_CR42","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1073\/pnas.0503726102","volume":"102","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff, C. A. et al. Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102, 9571\u20139576 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50029_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 30, 492\u2013500 (2016).","journal-title":"Leukemia."},{"key":"50029_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 28, 690\u2013714 (2015).","journal-title":"Cancer Cell."},{"key":"50029_CR45","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.imbio.2016.11.011","volume":"222","author":"A Sent\u00eds","year":"2017","unstructured":"Sent\u00eds, A. et al. Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology. 222, 620\u2013630 (2017).","journal-title":"Immunobiology."},{"key":"50029_CR46","doi-asserted-by":"publisher","first-page":"746","DOI":"10.4049\/jimmunol.1302848","volume":"193","author":"JM Lykken","year":"2014","unstructured":"Lykken, J. M. et al. Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice. J. Immunol. 193, 746\u2013756 (2014).","journal-title":"J. Immunol."},{"key":"50029_CR47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.4049\/jimmunol.1302661","volume":"192","author":"I Misumi","year":"2014","unstructured":"Misumi, I. & Whitmire, J. K. B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J. Immunol. 192, 1597\u20131608 (2014).","journal-title":"J. Immunol."},{"key":"50029_CR48","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny, P. et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. N. Engl. J. Med. 329, 1608\u20131614 (1993).","journal-title":"N. Engl. J. Med."},{"key":"50029_CR49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","volume":"186","author":"D Hamann","year":"1997","unstructured":"Hamann, D. et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407\u20131418 (1997).","journal-title":"J. Exp. Med."},{"key":"50029_CR50","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","volume":"18","author":"Y Godet","year":"2012","unstructured":"Godet, Y. et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin. Cancer Res. 18, 2943\u20132953 (2012).","journal-title":"Clin. Cancer Res."},{"key":"50029_CR51","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny, P. et al. Follicular lymphoma international prognostic index. Blood. 104, 1258\u20131265 (2004).","journal-title":"Blood."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50029-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50029-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:36:30Z","timestamp":1671266190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50029-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["50029"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-50029-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13471"}}